Globe Trotting
GE Healthcare, Indi Molecular to develop immune cell-targeted PET tracer candidates
GE Healthcare has collaborated with Indi Molecular to develop a diagnostic tool for the clinical management of immunotherapy patients. Under the deal, the partnership will involve the development of immune cell-targeted positron-emission tomography (PET) tracer candidates by using protein catalyzed capture (PCC) technology of Indi Molecular.
If successful, the tracer candidates will help in the identification of molecular markers of cytotoxic T-cells, as well as selection and monitoring of immunotherapy patients. The PET tracers will help better understand the patient’s immune cell profile and provide an early indication of whether he is likely to respond. It will help enhance clinical trial outcomes by optimizing the chances of immunotherapies successfully reaching the market.
Julia Casey
General Manager, Molecular Imaging
GE Healthcare
“With Indi Molecular as one of our collaborators, we can now begin to develop novel PET tracers for a variety of biomarkers of interest in the immuno-oncology space. These tracers could potentially play a critical role in supporting the development of immunotherapies, treatments that have shown great promise in how we manage oncology patients today.”
